|drug4114||standard chemotherapy Wiki||1.00|
|drug3564||UCPVax + Nivolumab Wiki||1.00|
|D002289||Carcinoma, Non-Small-Cell Lung NIH||0.45|
|D008175||Lung Neoplasms NIH||0.32|
There is one clinical trial.
The aim of this possible study is to identify if SARS-CoV-2 can be found in the tear film and conjunctiva of a patient with COVID-19.
Description: The primary endpoint is the number of conjunctival swabs tested positive for SARS-CoV2.Measure: SARS-CoV2 positive conjunctival swabs Time: 1 year
Description: The secondary target is the difference between the conjunctival swab tested positive for SARS-CoV2 and the nasopharyngeal swab.Measure: Conjunctival swab vs nasopharyngeal swab Time: 1 year
Description: In the case of a SARS-COV 2 positive conjunctival swab a virus culture will be conducted to clarify, whether it is a viable virus or virus RNA fragments.Measure: Viability of SARS-COV 2 Time: 1 year
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports